References
- Benson MD. Apolipoprotein AI and amyloidosis: a genetic model for aging. Kidney Int. 1998;53(2):508–509.
- Rader DJ, Gregg RE, Meng MS, et al. In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res. 1992;33(5):755–763.
- Rowczenio D, Dogan A, Theis JD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A–I. Am J Pathol. 2011;179(4):1978–1987.
- Das M, Wilson CJ, Mei X, et al. Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A–I: what makes the protein amyloidogenic? J Mol Biol. 2016;428(2):449–462.
- Gursky O, Mei X, Atkinson D. The crystal structure of the C-terminal truncated apolipoprotein A–I sheds new light on amyloid formation by the N-terminal fragment. Biochemistry. 2012;51(1):10–18.
- Satoskar AA, Burdge K, Cowden DJ, et al. Typing of amyloidosis in renal biopsies: diagnostic pitfalls. Arch Pathol Lab Med. 2007;131(6):917–922.
- Larsen CP, Beggs ML, Wilson JD, et al. Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico. Amyloid. 2016;23(2):119–123.
- Ramzy J, Mollee P, Kwok F, et al. LECT2 Amyloidosis: not just a Hispanic disease. 15th International Myeloma Workshop; 2015 Sep 23–26. p. e186 (abstract).